Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Biocogniv

Explore full profile

Biocogniv | AI-Powered Diagnostics for Hospitals

South Burlington, United StatesFounded 2019Health Tech & Medtech
Valuation $50–100M Last recorded · 2023
Revenue <$1M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Biocogniv and the history behind them.

About Biocogniv

Biocogniv is a pioneering startup in the healthcare technology sector, specializing in artificial intelligence (AI) diagnostics for acute care. The company focuses on developing AI-based biomarkers, which are measurable indicators of the severity or presence of some disease state, to enhance early diagnosis and intervention in emergency medicine. This technology aims to reduce the high mortality rates in U.S. hospitals, where over 700,000 patients die annually, with 1 in 20 of those deaths attributed to late diagnosis.

Biocogniv primarily serves hospitals and healthcare providers, including frontline medical staff and emergency departments. The company operates in the digital health market, a rapidly growing sector driven by the increasing adoption of AI and machine learning technologies in medical diagnostics.

The business model of Biocogniv revolves around the development and deployment of its AI diagnostic tools. These tools are integrated into hospital systems to assist medical professionals in making quicker and more accurate diagnoses. The company generates revenue through the sale and licensing of its diagnostic software to healthcare institutions. Additionally, Biocogniv may engage in partnerships and collaborations with other healthcare organizations to expand the reach and application of its technology.

Biocogniv has achieved significant milestones, including receiving FDA Breakthrough Device Designation for its sepsis diagnostic tool, which highlights its potential to provide more effective treatment options for patients. The company has also secured $6 million in seed funding led by Breyer Capital, which will be used to advance its digital diagnostic platform.

The leadership team at Biocogniv includes experienced professionals from both the healthcare and technology sectors, such as CEO and Founder Artur Adib, PhD, who has a background in computer science, biophysics, and quantum mechanics, and has held key positions at companies like Amazon and Twitter.

In summary, Biocogniv is at the forefront of integrating AI into acute care diagnostics, aiming to save lives through early and accurate disease detection.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
South Burlington, United States
Employees
4
Open positions
None listed
Dealroom signal
56.3/100
Industry
Health
Sub-industry
Health Platform
Sector
Health Tech & Medtech, Core AI, Tech for Hospitals and Clinics, Hard Tech, AI Applications, YC S20
Technology
Artificial Intelligence
Business model
SaaS
Client focus
b2b

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Oct 2023 $11M $43M Yamaha Motor · Breyer Capital ↗
SEEDOther financing Jan 2022 — — Unpopular Ventures —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Biocogniv website traffic

Latest recorded traffic for Biocogniv is 400 monthly website visits, down 13% over the last three months. Biocogniv's team declined 50% over the past year.

Latest monthly visits400 3-month web change-13% 1-year team growth-50%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A2 investors entered at this stage

Other known investors5 additional known investors

Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Biocogniv on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Biocogniv’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.